Adia Med Expands Into Wound Care, Targeting High-Demand $25 Billion Market and Unlocking New Growth Avenues
Adia Nutrition Inc. (OTCQB: ADIA) has announced its clinical division, Adia Med's expansion into the advanced wound care market, valued at $25.84 billion in 2025. The market is projected to reach $38.39 billion by 2034, driven by growing demand from 8.2 million Americans requiring chronic wound treatment annually.
The company will initially offer wound care services at its Winter Park, Florida clinic, with plans for expansion. Adia Med is already in-network with major insurers including UnitedHealthcare and Aetna, facilitating immediate patient access. The expansion targets high-reimbursement opportunities while addressing critical healthcare needs, particularly for diabetic foot ulcers, pressure sores, and post-surgical wounds.
Adia Nutrition Inc. (OTCQB: ADIA) ha annunciato l'espansione della sua divisione clinica, Adia Med, nel mercato dell'assistenza avanzata alle ferite, stimato a $25.84 miliardi nel 2025. Si prevede che il mercato raggiungerà $38.39 miliardi entro il 2034, trainato dalla crescente domanda di cura per le ferite croniche da parte di 8,2 milioni di americani ogni anno.
La società offrirà inizialmente servizi di cura delle ferite nella sua clinica di Winter Park, Florida, con piani di espansione. Adia Med è già in rete con importanti assicuratori come UnitedHealthcare e Aetna, agevolando l'accesso immediato dei pazienti. L'espansione punta a opportunità con rimborsi elevati, rispondendo al contempo a necessità sanitarie critiche, in particolare per ulcere del piede diabetico, piaghe da decubito e ferite post-chirurgiche.
Adia Nutrition Inc. (OTCQB: ADIA) ha anunciado la expansión de su división clínica, Adia Med, en el mercado de cuidados avanzados de heridas, valorado en $25.84 mil millones en 2025. Se proyecta que el mercado alcanzará $38.39 mil millones para 2034, impulsado por la creciente demanda de tratamiento para heridas crónicas de 8.2 millones de estadounidenses cada año.
La compañía ofrecerá inicialmente servicios de atención de heridas en su clínica de Winter Park, Florida, con planes de expansión. Adia Med ya forma parte de la red de aseguradoras importantes como UnitedHealthcare y Aetna, facilitando el acceso inmediato de los pacientes. La expansión apunta a oportunidades de alta retribución mientras atiende necesidades sanitarias críticas, especialmente úlceras del pie diabético, escaras y heridas postoperatorias.
Adia Nutrition Inc. (OTCQB: ADIA)는 임상 부문인 Adia Med가 2025년 기준 $25.84억 달러 규모로 평가되는 고급 상처 치료 시장으로 확장한다고 발표했습니다. 이 시장은 매년 만성 상처 치료가 필요한 820만 명의 미국인으로 인해 2034년까지 $38.39억 달러에 이를 것으로 예상됩니다.
회사는 우선 플로리다주 윈터파크에 있는 클리닉에서 상처 치료 서비스를 제공할 예정이며 향후 확장을 계획하고 있습니다. Adia Med는 이미 UnitedHealthcare와 Aetna 등 주요 보험사 네트워크에 포함되어 있어 환자들이 즉시 서비스를 이용할 수 있습니다. 이번 확장은 높은 보험 수가 기회를 겨냥하는 동시에 당뇨발 궤양, 욕창 및 수술 후 상처 등 중요한 의료 수요를 해결하는 데 목적이 있습니다.
Adia Nutrition Inc. (OTCQB: ADIA) a annoncé l'expansion de sa division clinique, Adia Med, sur le marché des soins avancés des plaies, évalué à 25,84 milliards de dollars en 2025. Ce marché devrait atteindre 38,39 milliards de dollars d'ici 2034, porté par la demande croissante de traitement des plaies chroniques de 8,2 millions d'Américains chaque année.
L'entreprise proposera dans un premier temps des services de soin des plaies dans sa clinique de Winter Park, en Floride, avec des plans d'expansion. Adia Med fait déjà partie des réseaux de grands assureurs tels que UnitedHealthcare et Aetna, facilitant l'accès immédiat des patients. L'expansion vise des opportunités à forte rémunération tout en répondant à des besoins de santé critiques, notamment les ulcères du pied diabétique, les escarres et les plaies post-opératoires.
Adia Nutrition Inc. (OTCQB: ADIA) hat angekündigt, dass seine klinische Sparte Adia Med in den Markt für fortgeschrittene Wundversorgung expandiert, der 2025 auf $25.84 Milliarden geschätzt wird. Für 2034 wird ein Anstieg auf $38.39 Milliarden erwartet, angetrieben durch die wachsende Nachfrage von jährlich 8,2 Millionen Amerikanern, die eine Behandlung chronischer Wunden benötigen.
Das Unternehmen wird zunächst Wundversorgungsleistungen in seiner Klinik in Winter Park, Florida, anbieten und plant eine Ausweitung. Adia Med ist bereits im Netz großer Versicherer wie UnitedHealthcare und Aetna, was den unmittelbaren Zugang für Patienten erleichtert. Die Expansion zielt auf hochvergütete Möglichkeiten ab und adressiert zugleich dringende medizinische Bedürfnisse, insbesondere diabetische Fußgeschwüre, Druckgeschwüre und postchirurgische Wunden.
- Entry into large $25.84 billion wound care market with projected growth to $38.39 billion by 2034
- Existing insurance partnerships with major providers UnitedHealthcare and Aetna
- High-reimbursement category with strong insurance support
- Large addressable market of 8.2 million Americans requiring wound care annually
- Initial operations limited to single Winter Park, Florida clinic
- Entering competitive market with established players
- Success dependent on patient volume and insurance approvals
Winter Park, Florida--(Newsfile Corp. - August 20, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company at the forefront of regenerative medicine and personalized health solutions, today announced that its clinical division, Adia Med, is officially expanding into the high-demand field of advanced wound care. This strategic move enables the company to serve a wider patient base, meet a critical and growing healthcare need, and open a new stream of revenue that supports long-term shareholder value.
Every year, an estimated 8.2 million Americans require medical treatment for chronic wounds, including diabetic foot ulcers, pressure sores, post-surgical wounds, and injuries resulting from poor circulation. These conditions are particularly prevalent among older adults and individuals with diabetes or vascular disease. Of those patients, approximately 1.6 million undergo skin graft procedures annually as part of their treatment and recovery process. As the population ages and chronic diseases become more widespread, the demand for advanced wound care is expected to rise sharply over the next decade.
The wound care market is valued at
By entering this sector, Adia Med is responding directly to market demand while establishing a scalable revenue stream that aligns with its broader clinical strategy. The company will begin offering wound care services at its flagship Winter Park, Florida clinic, with plans to expand based on patient volume, clinical partnerships, and insurance approval. Services will include personalized wound evaluations, evidence-based protocols, and regenerative support therapies designed to accelerate healing, reduce complications, and improve patient outcomes.
"This expansion into wound care is both a mission-driven and market-smart decision," said Larry Powalisz, CEO of Adia Nutrition Inc. "We're addressing a real and growing problem that impacts millions of people, while also adding a new layer of value for our shareholders. Wound care represents a stable, high-reimbursement category with strong insurance support and we're stepping in with the tools, talent, and strategy to do it right."
Adia Med is currently in-network with major insurance providers including UnitedHealthcare and Aetna, positioning the company to make wound care services accessible and affordable for a large number of patients from day one. This move also reinforces Adia Med's commitment to integrated, whole-person care by adding a new service line that complements its existing wellness and regenerative health offerings.
As the company continues to grow, wound care will serve as both a meaningful healthcare solution and a durable revenue vertical contributing to Adia Med's mission of expanding access, driving innovation, and delivering sustainable returns for investors.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262972
FAQ
What is the size of the wound care market that Adia Med (OTCQB: ADIA) is entering?
How many patients require wound care treatment in the US according to Adia Med?
Which insurance providers is Adia Med in-network with for wound care services?
Where will Adia Med initially offer its wound care services?
What types of wounds will Adia Med treat in its new wound care division?
